Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.

Publikation

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.

Wissenschaftlicher Artikel/Review - 21.11.2023

Wagner Nikolaus, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, Fuchß Milena, Ring Natalie, Stäger Ramon, Zellweger Caroline, Ebel Chiara, Kimeswenger Susanne, Oellinger Angela, Amaral Teresa, Forschner Andrea, Leiter Ulrike, Klumpp Bernhard, Hoetzenecker Wolfram, Terheyden Patrick, Mangana Joanna, Loquai Carmen, Cozzio Antonio, Garbe Claus, Meier Friedegund, Eigentler Thomas Kurt, Flatz Lukas

Zitation

Wagner N, Lenders M, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler T, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. Eur J Cancer 2023; 196:113425.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur J Cancer 2023; 196

Veröffentlichungsdatum

21.11.2023

eISSN (Online)

1879-0852

Seiten

113425

Kurzbeschreibung/Zielsetzung

Targeted therapy (TT) of BRAF V600 mutated unresectable melanoma with inhibitors of the MAPK pathway achieves response rates of up to 76%, but most patients develop secondary resistance. Albeit TT is strikingly efficacious during the first days of treatment, even in advanced cases, long-term survival is highly unlikely, especially in patients with unfavorable baseline characteristics like elevated lactate dehydrogenase (LDH). In patients treated with anti-PD-1 immune checkpoint inhibitors, elevated baseline metastatic growth rate (MGR) was the most important prognostic factor. Here, we aimed at investigating the prognostic impact of MGR in patients with unresectable melanoma receiving TT.